Market Cap: $2.21B
XI
Xencor, Inc.
XNCR
NASDAQ (NASDAQ Global Market)USD
Market Cap: $2.21B
Xencor Adjusts Revenue Outlook for Ultomiris Royalties Amid Market Changes In a recent announcement, Xencor Inc. recognizes the necessity to revise its revenue outlook specifically related to royaltie…
Xencor Takes Strategic Steps to Reassess Revenue Projections for Ultomiris Xencor Inc. announces a revision of its revenue outlook regarding royalties from Ultomiris, a drug that plays a significant r…
Xencor Adjusts Revenue Outlook for Ultomiris Royalties Xencor Inc. has announced a revision to its revenue outlook concerning royalties from Ultomiris, a key product in its pharmaceutical portfolio. T…
Innovative Approaches in Cancer Immunotherapy: GT Biopharma's Progress GT Biopharma, Inc., a clinical-stage biotechnology company based in San Francisco, is making notable strides in the field of immu…
Xencor Advances Engineered Antibodies Through Upcoming Conferences Xencor, Inc., a clinical-stage biopharmaceutical company, is poised to showcase its innovative approach to engineered antibodies at s…
Xencor Showcases Innovative Antibody Development at Upcoming Conferences Xencor, Inc., a clinical-stage biopharmaceutical company, is poised to highlight its advancements in engineered antibodies for…
Xencor Advances in Autoimmune Disease Treatments and Clinical Pipeline Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies, is making notable strides in its…
Xencor Advances Clinical Pipeline with New Autoimmune Programs Xencor, Inc., a clinical-stage biopharmaceutical company renowned for its innovative engineered antibodies, announces significant develop…